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Abstract
Background: Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder, and
accounts for 8% of individuals with moderate or severe dizziness. BPPV patients experience substantial inconveniences
and disabilities during symptomatic periods. BPPV therapeutic processes – the Dix-Hallpike Test (DHT) and the Canalith
Repositioning Maneuver (CRM) – have an evidence base that is at the clinical practice guideline level. The most
commonly used CRM is the modified Epley maneuver. The DHT is the gold standard test for BPPV and the CRM is
supported by numerous randomized controlled trials and systematic reviews. Despite this, BPPV care processes are
underutilized.
Methods/design: This is a stepped-wedge, randomized clinical trial of a multi-faceted educational and care-process-
based intervention designed to improve the guideline-concordant care of patients with BPPV presenting to the
emergency department (ED) with dizziness. The unit of randomization and target of intervention is the hospital. After
an initial observation period, the six hospitals will undergo the intervention in five waves (two closely integrated
hospitals will be paired). The order will be randomized. The primary endpoint is measured at the individual patient
level, and is the presence of documentation of either the Dix-Hallpike Test or CRM. The secondary endpoints are
referral to a health care provider qualified to treat dizziness for CRM and 90-day stroke rates following an ED dizziness
visit. Formative evaluations are also performed to monitor and identify potential and actual influences on the progress
and effectiveness of the implementation efforts.
Discussion: If this study safely increases documentation of the DHT/CRM, this will be an important step in implementing
the use of these evidenced-based processes of care. Positive results will support conducting larger-scale follow-up studies
that assess patient outcomes. The data collection also enables evaluation of potential and actual influences on the
progress and effectiveness of the implementation efforts.
Trial registration: ClinicalTrials.gov, ID: NCT02809599. The record was first available to the public on 22 June 2016 prior to
the enrollment of the first patients in October 2016.
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Background
Benign paroxysmal positional vertigo (BPPV) is the most
common peripheral vestibular disorder with a lifetime
prevalence of 2.4% [1]. BPPV accounts for 8% of individ-
uals with moderate or severe dizziness [1]. “Benign” is a
misnomer in the label of “benign paroxysmal positional
vertigo.” BPPV patients experience substantial inconve-
niences and disabilities during symptomatic periods [1, 2].
Nearly one in four BPPV patients stop driving a car, one
in three miss work, and more than three in four seek med-
ical consultation [1].
BPPV processes – the Dix-Hallpike Test (DHT) and the
Canalith Repositioning Maneuver (CRM) – have an evidence
base that is at the clinical practice guideline level [3, 4]. The
most commonly used CRM is the modified Epley maneuver.
The DHT is the gold standard test for DHTand the CRM is
supported by numerous randomized controlled trials (RCTs),
and systematic reviews [5–12].
The problem is that BPPV processes are substantially
underutilized. Evidence from our work and others indi-
cates substantial underutilization of the DHT and CRM
[1, 13]. Prior epidemiological studies indicate that less
than 10% of BPPV patients are treated with the CRM [1].
Our preliminary studies indicate that 78% of patients diag-
nosed with BPPV in the emergency department (ED) did
not have the DHT documented and 96.1% did not have a
CRM documented. The reasons for the underuse of these
processes has not been systematically studied and is likely
to be complex, involving several constructs including
knowledge gaps, clinical inertia, and low provider
self-efficacy. The DHT is used to identify BPPV.
Identification of BPPV: the Dix-Hallpike Test (DHT)
The DHT is the gold standard test for BPPV [3, 4]. It is a
simple bedside test. A positive test is indicated by
up-beating and torsional nystagmus lasting about 10–20 s.
Even when physicians use the DHT, there is the possibility
that they may not interpret the results correctly [14–16].
Common errors include calling the test positive for symp-
toms (rather than nystagmus), and making a BPPV diag-
nosis when there is any pattern of nystagmus observed
[17]. Clinicians must be aware that different patterns of
positional nystagmus can be triggered by other disorders.
For example, patients with vestibular neuritis have hori-
zontal and persistent (not transient) nystagmus that may
be most apparent during positional testing. Central disor-
ders can also cause positional nystagmus, typically persist-
ent – not transient – down-beating nystagmus.
Treatment of BPPV: the Canalith Repositioning Maneuver
(CRM)
The CRM is the treatment for BPPV. The CRM is used
to move the canaliths from the inferior portion of the in-
volved posterior canal back into the central chamber of
the inner ear [3]. In this location, the positional vertigo
no longer occurs. The first two steps of the CRM are the
same as the DHT. If the DHT is positive on the right
side, then there are only three more steps that are used
to move the particles out of the canal.
Relevance and priority for this study
The topic is high impact in terms of the number of
patients affected (BPPV lifetime prevalence is 2.4% [1]),
efficacy of the CRM [3, 4], and health care efficiencies
[1, 13, 18–20]. These factors, and low utilization in the
ED setting, justify implementation research. We bring
together investigators of multiple disciplines – including
emergency medicine (academic and community prac-
tice), neurology, otolaryngology (ENT), general medi-
cine, behavioral science, and implementation science –
with the goal of helping physicians address a problem
they have declared to be a top priority for decision sup-
port and which is associated with high frequency of un-
necessary testing, such as head computed tomography
(CT) scanning and low frequency use of evidence-based
practices [1, 13, 18–21]. This project could have a direct
positive impact on the effectiveness and efficiency of
care for BPPV presentations, and others.
Frontline physicians want support for vertigo. A sur-
vey of ED physicians about priorities for the develop-
ment of clinical decision support (1150 respondents)
ranked vertigo as the #1 topic in adult ED presentations
[21]. The “lowest-hanging fruit” in the opportunity to
achieve meaningful improvements in dizziness presenta-
tions is BPPV. BPPV is common, and readily identifiable
and treatable at the bedside. No laboratory or imaging
studies are needed, and in fact these are explicitly dis-
couraged in guideline statements [4]. ED physicians have
strongly advocated for the use of BPPV processes (even
stopping an ED-based trial for ethical reasons given the
effect size at interim analysis) [5], and our survey (pre-
liminary studies) indicates high demand for BPPV
intervention.
Supporting data
Two evidence-based guidelines support the DHT and the
CRM to diagnose and treat BPPV. Evidence-based guide-
lines supporting the DHT and CRM were published in
2008 by the American Academy of Otolaryngology-Head
and Neck Surgery and the American Academy of Neur-
ology [3, 4]. Additional systematic reviews also support
the DHT and CRM [6, 7, 12, 22, 23]. The primary RCTs
demonstrate the resolution of BPPV symptoms (outcomes
measured at 1 day to 4 weeks) in patients treated with the
CRM [9–11, 24, 25]. In these studies, 61 to 80% of treated
patients had resolution after just one treatment compared
with 10 to 48% of untreated patients. These effect sizes
translate in to a number-needed-to treat ranging from 1.4
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to 3.7, which is among the most substantial effects achiev-
able in clinical medicine. In the study assessing outcome
at 24-h, 80% of treated patients were cured versus only
10% of controls [24]. Substantial benefit has also been
demonstrated in RCTs from primary care settings [5, 8].
Aims and objectives
Primary objective
The primary hypothesis focuses on BPPV diagnosis is
that we will observe different proportions of the primary
endpoint (documentation of the DHT or CRM) in ED
visits before and after the intervention.
Secondary objectives
 Main secondary hypothesis (focuses on BPPV
treatment): we will observe different proportions of
the secondary endpoint (documentation of the DHT
or CRM or outpatient referral for BPPV evaluation
to an appropriate provider) in ED visits before and
after the intervention. This objective is broader than
the primary as it allows referral. The analysis plan
will provide the specific number of patients having
each of the three components (DHT, CRM, or
referral – see the first exploratory objective below)
 Main safety objective – to determine the cumulative
incidence of short-term (90-day) stroke within the
ED dizziness population aged 45 years and older,
both before and after the intervention
Exploratory objectives
 Characterize utilization in each individual type of
BPPV care process (DHT, CRM, or referral to BPPV
provider) across the treatment groups
 Characterize proportions of visits with BPPV
process utilization at individual provider (physician,
resident, or advanced practice provider) level, both
before and after the intervention
 Characterize changes in length of stay in the ED
associated with the intervention, both before and
after the intervention
 Characterize changes in the utilization of neuro-
imaging studies and hospital admission, both before
and after the intervention
 Characterize changes in overall costs, both before
and after the intervention
 Determine the cumulative incidence of repeat ED
dizziness visits, both before and after the
intervention
 Determine the proportion of index visit stroke
diagnosis in the ED dizziness population in the
population aged 45 years and above
 Estimate the proportion of cases receiving
documentation consistent with guideline concordant
care (composite of the DHT performed in patients
without nystagmus or focal neurological deficit;
DHT only interpreted as positive with positive
documentation of triggered, transient nystagmus)
 Estimate relationship between intensity of
intervention contact (time spent on website,
attendance at continuing medical education (CME)
sessions, hours of academic detailing provided) and
change in BPPV diagnostic and treatment endpoints
before and after the intervention
 Describe adverse events proximally related to the
performance of the DHT or CRM in the ED
Methods/design
Design overview
This is a partnered best-practice implementation study,
meaning that the local providers will be engaged in the
intervention components. The testing design method is
a stepped-wedge, randomized clinical trial of a
multi-faceted educational and care-process-based inter-
vention designed to improve the guideline-concordant
care of patients with BPPV in the ED. The
stepped-wedge design has the advantages of being ac-
ceptable to stakeholders when the intervention imple-
ments evidence-based practice, initiation of the
intervention at multiple time points (when a single time
point is not logistically feasible), and including contem-
poraneous controls to evaluate and adjust for secular
trends [26]. For this study, the delivery of the interven-
tion to all sites also had the advantage of enabling us to
explore variation in implementation fidelity across the
mix of sites. The unit of randomization is the hospital.
After an initial observation period, the six hospitals will
undergo the intervention in five waves (the two closely
integrated hospitals will be paired) – see Fig. 1. The
order in which each hospital receives the intervention
will be randomized. The intervention will be provided as
a complete package during the month that each hospital
is randomized.
The current design will allow us to estimate the
amount of change in the use of guideline-concordant
BPPV care processes that is associated with the delivery
of the intervention. Each hospital will serve as its own
control providing pre and post observations. Since this
is stepped-wedge, some hospitals will contribute many
more pre-intervention observations and this will allow
us to observe for underlying secular trends to ensure
that changes observed in care processes are attributable
to the interventions.
The focus of the intervention is on health systems and
frontline medical providers; however, the observations
and outcomes are derived from the medical records of
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identified cases of dizziness in the included EDs. As pa-
tients are not directly intervened upon, and the inter-
vention is to improve guideline-concordant care, we use
a waiver of informed consent for the collection of
patient-level outcomes from the medical record, along
with a waiver of documentation of informed consent for
brief phone interviews and Short message service (SMS)
and online surveys with patients.
Health care providers involved in the study will be in-
formed of the voluntary nature of this research and will
not be required to use any tools or attend any educa-
tional sessions provided by this team (see Add-
itional file 1: Medical provider protocol).
Patient population and setting
The setting for this study is the six hospital-affiliated,
EDs in Nueces County, TX, USA. The largest city in Nu-
eces County is Corpus Christi. The community of Cor-
pus Christi was initially identified as an ideal location for
these population-based studies because of the geo-
graphic isolation from other cities and the focus on rep-
resentative community practice. These characteristics
mean that the majority of acute illness presentations by
Nueces County residents will occur within the Nueces
County medical facilities and the medical care provided
will be more generalizable to other communities than
the care that is provided at large, tertiary-care referral
centers. Given our extensive prior work in Nueces
County, we have also developed long-standing relation-
ships with providers, administrators, and other persons
in Nueces County. The University of Michigan has a
field office in Corpus Christi with approximately 10–15
full-time employees.
Eligibility and enrollment
The dizziness visits are the unit of analysis for the pri-
mary measure of use of BPPV processes by the health
care providers.
Inclusion criteria for dizziness visit medical record review
and data abstraction
 Aged 18 years or older
 ED patient seen at one of six full-service, non-
freestanding EDs in Nueces County, TX, USA
 Principal dizziness case: the triage reason for visit is
a dizziness symptom or a dizziness symptom is one
of the first three listed complaints in physician
medical record or a dizziness diagnosis (e.g.,
dizziness or vertigo not otherwise specified (NOS),
BPPV, vestibular neuritis) is recorded as one of the
first three final ED diagnoses
Exclusion criteria
 Prisoners
STUDY PERIOD
Enrolment Allocation Close-out
TIMEPOINT** -t1 0 t1 t2 t3 t4 t5 t6 t7 t8
ENROLMENT:
Eligibility screen X
Site champion 
selection X
Randomization X
Allocation X
INTERVENTIONS:
After initial 
observational 
period (t1) 
hospitals receive 
educational 
intervention in 5 
waves.
X
X
X
X
X
ASSESSMENTS:
Measure Dizziness 
Outcome
X X X X X X
Measure 90 Day 
Stroke Events
X X X X X X
Fig. 1 Timing of study events at hospital level
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 Cognitively impaired adult (defined for study
purposes as notation of mental retardation or similar
diagnosis within the chart)
Study procedures
Hospital inclusion – Data collection will commence in
the pre-intervention period and at that point, the hospi-
tals will be engaged in research.
Identification of cases
Cases of dizziness presentations will be captured by ac-
tive and passive surveillance. Study abstractors will be
blinded to randomization periods and groups. For active
surveillance, ED logs will be screened for dizziness terms
(e.g., dizziness, vertigo, imbalance, spinning, lightheaded-
ness, nausea, common misspellings or similar terms) as
the patients’ reasons for visiting the ED. Passive surveil-
lance will be performed by screening an International
Classification of Diseases, versions 9/10 (ICD-9/10) hos-
pital database for dizziness and vestibular ICD-9/10
codes. We do not limit the population to patients receiv-
ing a BPPV diagnosis for the following reasons: the like-
lihood of diagnostic misclassification [17, 20], the high
frequency of cases receiving symptom only diagnoses
(see preliminary results), and diagnostic bias introduced
by the intervention during the post-intervention phase
(e.g., providers may be more likely to use BPPV diagno-
ses after the intervention).
Screening and enrollment
All cases meeting the inclusion criteria and the defin-
ition of principal dizziness visit will undergo data ab-
straction and will be included in the overall trial
database. We will collect monthly counts of the number
of charts with any screening dizziness terms at each site.
Consent/assent procedures – patient-level data collection
Patients will be receiving routine clinical care at the local
EDs and we have sought a waiver for review and
collection of data from the medical charts. For follow-up
telephone surveys of patients in the ED, we will use a
structured script to provide information about the study
and get informed consent to ask brief questions about
the performance of BPPV care processes in the ED. For
the SMS and online surveys, patients will be asked to
opt in if they are willing to complete the study
questions.
Intervention group assignment
Patients will be assigned to either the intervention or
control group based on the time and hospital they
present to for their dizziness care. If the hospital has re-
ceived the intervention and is in the post-intervention
period – they will be in the intervention group; other-
wise, they will be considered control patients (pre-inter-
vention). The hospitals will receive the intervention at a
randomly assigned time point.
Study interventions
The overall educational intervention is delivered at the
hospital level. Table 1 provides an overview of the
hospital-level interventions that occur as part of the trial.
Attendance by medical providers will be tracked to deter-
mine utilization.
Champion development
Local ED physician champions will be recruited for each
hospital system. These champions will serve as the point
person of contact for the local ED physician groups, will
receive more focused training on BPPV prior to the
CME sessions, will be a key participant (instructor) at
the CME session, will lead follow-up educational ses-
sions, and be available for questions as needed.
Interactive high-yield, hands-on education session (CME
session)
An evidence-based educational session will be developed
to be presented by Drs. Kerber, Meurer, and local
Table 1 Multi-faceted intervention overview
Implementation strategy components Component description
1. Local champions Local champions (ED providers) will be recruited and trained in BPPV testing and diagnosis. Each will
participate in the CME session, follow-up sustainability session, and commit to help during routine care
2. Educational sessions. Interactive and
hands-on sessions
Sessions will review BPPV mechanisms and evidence, utilize videos, include hands-on demonstration,
and address barriers from aim 1
3. Decision aid. Multi-media web-based
decision aid application
Includes high-yield text and videos on the BPPV processes and characteristic exam findings. Audit and
Feedback – split out as its own row. Will also include individual- and group-level feedback on dizziness
care process delivery over time
4. Referral resource Readily available list of outpatient, experienced, BPPV providers accepting referrals
5. Follow-up educational sessions Sessions, led by local champions, to facilitate adoption, implementation, and sustainability
6. Partnered development and other
resources
Other resources, identified by and developed by the local medical providers may be provided
BPPV benign paroxysmal positional vertigo, CME continuing medical education, ED emergency department
Meurer et al. Trials          (2018) 19:697 Page 5 of 11
champions to the Corpus Christi ED physicians, physi-
cians assistants, and residents and will be used to intro-
duce the decision aid. Common barriers will be addressed
along with suggestions for overcoming barriers. For ex-
ample, we anticipate that one barrier in the ED will be
small examination gurneys. Throughout the session, vid-
eos will be used to enhance learning. Videos will demon-
strate the DHT and CRM, the characteristic BPPV
nystagmus, and other eye movements that can be misin-
terpreted as BPPV nystagmus (e.g., eyelid blinks, voluntary
movements, and nystagmus patterns of vestibular neuritis,
or a central lesion). Descriptions of factors that could lead
to misclassification of BPPV cases based on the DHT will
be provided, such as extremely slow movements or basing
the test interpretation on symptoms rather than the char-
acteristic pattern of nystagmus. A specific part of the ses-
sion will focus on risks of the BPPV processes and
dangerous mimickers of BPPV. It will be made clear that
the processes should be considered contraindicated in pa-
tients with known or suspected cervical spine instability
until spinal stability has been ascertained. Interactive tech-
niques will be incorporated to maximize the probability of
outcome success by adhering to principles of adult educa-
tion: delivering content in a learner-centered, active for-
mat, relative to the learner’s needs, which is
simultaneously engaging and reinforcing [26]. The ses-
sions will target increasing self-efficacy (perception of
one’s abilities) and outcome expectancy (belief that a be-
havior will lead to the desired outcome). High outcome
expectancy is associated with an increased likelihood of
performing a behavior [27]. Hands-on training for the
DHT and CRM will also be developed as part of the pres-
entation. Physicians will pair up at tables and perform the
DHT and CRM under instructor guidance (i.e., investiga-
tors and champions). Models of the semicircular canals
will be used to facilitate understanding the basis for the
processes. CME credit and a modest incentive US$50 will
be offered to encourage medical provider attendance. In-
dividual attendance will be recorded. To promote the wid-
est exposure of the educational sessions, the sessions will
also be video recorded and made available for post-inter-
vention physicians and medical providers to review on
their own time. In addition, individual or small group ses-
sions will be offered for providers not able to attend the
primary sessions. To improve later presentations, the pro-
ject team will review recordings of CME sessions.
Web-based, multi-media, real-time decision aid
We have developed a web-based application in accordance
with the findings from physician interviews and environ-
ment barrier assessments (http://www.dizztinct.com). This
aid is a tool providers will be able to efficiently use at the
point of care. Extensive collaborations with our behavioral
scientists and technology developers informed the content
and structure of this aid. We plan for providers to be able
to use the aid in less than 10min, though it will also
include additional resources and information so that more
details are available for interested providers. The aid uses
videos and includes brief, high-yield narration, video
instructions on the DHT and CRM, and video demonstra-
tions of positive and negative test results. The videos
demonstrate dangerous signs of central nervous system
disorders. The aid also highlights potential risks of the
processes and BPPV mimickers. Additionally, it states that
known or suspected cervical spine instability is a
contraindication until spinal stability has been ascertained.
The aid will be password protected to each individual’s
identity.
The aid will also contain tailored data on the individual’s
performance on dizziness care processes. The proportion
of eligible dizziness cases receiving the DHT (primary
BPPV diagnostic endpoint) and the CRM (secondary
BPPV therapeutic endpoint), will be plotted over time.
This will be graphically summarized to demonstrate the
performance of all health care providers (anonymized to
user) at the site over time, and the individual data point
corresponding to the user will be noted in a monthly
email and within the website. The aid will also be available
in a mobile version for smartphones and tablets.
Referral resource
Because our main goal is to get the right treatment to
the right patient within a reasonable time frame, we will
also establish a list of providers in the community who
evaluate and treat BPPV. The goal of this system is to
provide ED physicians with a more informed route of re-
ferral to appropriate community providers for BPPV
treatment. Many providers who see patients with BPPV
or probable BPPV would like to make a specific referral
to another provider for evaluation, treatment, or subse-
quent assessment. Our previous survey work of commu-
nity ED providers found this to be a popular option. To
establish this resource, providers in the community who
evaluate and treat BPPV will be identified, covering a
variety of insurance/payment options. Physical thera-
pists, particularly those with training in vestibular ther-
apy, are likely to be an important resource. We have
already been in contact with PTs in the community in
this regard. A system will be established to track use of
referrals. In general, we will use the existing hospital
methodology for referrals; however, we may be able to
augment this with a list of local providers who are will-
ing and able to quickly see and treat these patients.
Follow-up educational sessions
Follow-up maintenance sessions will also be developed for
the time period after the first CME session. These sessions
will be used to facilitate adoption, implementation, and
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sustainability. The format of follow-up sessions will be
case-based. Providers will be encouraged to express suc-
cesses and failures. Feedback on BPPV processes
utilization will be presented. These sessions may be led by
the designated local champion, an interested local medical
provider, or the study team. These sessions may be in per-
son or by telephone or web conference.
Partnered adaptations of other resources identified by local
medical providers
This is a partnered implementation project, and based
on our engagement with the providers during the project
we expect to learn even more about provider preferences
and needs based on provider feedback. The intervention
components can be adjusted/adapted based on provider
feedback and requests, consistent with the approved
protocol for this research. For example, it is possible that
providers may request additional resources or
patient-specific materials. If they make such a request,
we will help them in finding/developing/implementing
such other resources. We, as the researchers, will not
generate such materials ourselves without proper regula-
tory approval.
Dizziness Checklist (introduced in protocol version 2.0)
In the course of engaging with providers, they requested
an additional website/app component to prospectively
collect information related to safety in discharging ED
dizziness patients home. We worked with providers to
develop a list of items and a data collection form. The
list of items includes the BPPV-specific items and add-
itional items that largely relate to the possibility that the
patient might have a stroke as the cause or is high risk
for stroke in the short term. Both of these components
fit well with our overall intervention which emphasizes
both the features of BPPV and also findings that suggest
an alternative cause such as stroke. The addition of this
component could serve to: (1) increase exposure to the
BPPV related items (an additional resource providers
may seek out), (2) enhance data capture in a subsample
of visits, and (3) build engagement/collaboration with
local providers. The new prospective data collection
could enhance implementation fidelity measures because
this prospective provider-entered data enables an assess-
ment of the consistency of medical record documenta-
tion of BPPV assessments. In addition, the new
prospective data regarding safety items should enhance
secondary analysis regarding the 90-day stroke rate by
informing factors that predict stroke (in the subsample
with data collected).
In the form, we separate the BPPV items from the safety
items to enforce that the BPPV items are established clin-
ical guideline items but that the safety items are not. The
form also explicitly states that the safety items are for data
collection purposes only. There is no current society clin-
ical guideline regarding safety in discharge of ED dizziness
patients. To develop these items, we reviewed the medical
literature regarding factors previously shown to predict
stroke. The items were then created/edited by our team of
investigators (neurologists, emergency medicine, ENT,
general medicine) and local ED providers. If the analysis
of these safety items indicates they are accurate in dis-
criminating stroke, then future studies (requiring separate
Institutional Review Board (IRB) application) may be done
to test the effect of the list on outcomes in dizziness ED
cases (e.g., subsequent stroke event, length of stay in the
ED, test utilization).
The form will be available on the website/app. Pro-
viders can voluntarily complete the form at the point of
care. Data can be entered electronically, or paper forms
can be printed, completed, and inserted into a lock-box
in the ED.
Randomization
The overall study period will be approximately 18
months. The first 4 months is the pre-intervention
period. After this, the sites will receive the intervention
in five waves occurring approximately every 2 months.
The randomization sequence was generated using a spe-
cific R program written by WJM with a specific random
number seed (to allow for reproducibility). (Two closely
integrated hospitals which have almost complete overlap
in providers will receive the intervention at the same
time.) Finally, there will be approximately 4 months
where all sites will be in the post-intervention period.
Therefore, each site will have distinct pre- and
post-intervention times.
Concomitant interventions
The community will be closely monitored for interventions
that may change the underlying diagnosis or treatment of
BPPV (i.e., a health insurer or malpractice-insurer-based
intervention on the care of dizziness in the ED.) The pri-
mary analysis will remain unchanged, but secondary ana-
lyses will be conducted to estimate the impact of this
change within hospitals that have and have not received the
intervention by the time of the event.
Adverse experiences
The definitions of adverse events (AEs), and serious ad-
verse events (SAEs) are available in the protocol as Add-
itional files 1, 2, 3, and 4.
Statistical considerations
Endpoint
The primary endpoint (BPPV diagnosis) is measured at
the individual patient level, and is the presence of
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documentation of either the DHT or CRM (since the
first step of the CRM is the diagnostic maneuver).
Secondary endpoints (BPPV treatment) are composite
(any) of following three items: (1) Documentation of
DHT alone in the ED, (2) Documentation of CRM dur-
ing ED visit, (3) Outpatient referral to a BPPV provider
(ENT surgeon, neurologist, physical therapist).
Safety secondary endpoint: 90-day cumulative inci-
dence of stroke in patients aged 45 years and above fol-
lowing initial ED discharge home visit for dizziness.
Validated stroke event will be obtained by data linkage
with an on-going stroke surveillance study in the same
medical systems: The Brain Attack Surveillance In Cor-
pus Christi (BASIC) project [27].
Additional exploratory endpoints: each of the individ-
ual components of the composite secondary endpoint
(DHT, CRM, or referral), stroke at index ED dizziness
visit, ED length of stay in hours, neuro-imaging
utilization, and inpatient hospitalization utilization.
Validity of primary endpoint: the primary endpoint has
been rigorously evaluated in our preliminary work [28].
The documentation of performance of BPPV care pro-
cesses is rare, and, in discussion with physicians in emer-
gency medicine practice, the rarity of documentation is
well reflected in clinical practice: BPPV care processes
are rarely used and rarely documented. In addition, a
second reviewer who was blinded to treatment group as-
signment (pre versus post intervention based on time
within site) reviewed each chart to determine the pres-
ence or absence of the primary endpoint.
Sample size and accrual
The trial will start with an initial no intervention period of
approximately 4 months followed by randomized stag-
gered intervention with a new hospital entering approxi-
mately every 2months, finalized by approximately four
post-intervention months will result in the approximately
balanced number of 867 visits occurring without interven-
tion and 933 visits occurring under (post) intervention.
We chose this timing to balance the amount of overall re-
sources (grant funding) we had for data collection with
having adequate separation between each intervention
and having a sufficient post-intervention period to observe
response to intervention. This calculation assumes the
average anticipated total patient visit rate of 100 patients
per month. Based on our pilot studies and the literature
we expect the DHT or CRM procedure to be done in 5%
patients before the intervention. With the expected num-
ber of visits calculated above, we will be able to detect the
increased DHT or CRM rate of 9% and above with 90%
power by a two-sided test at the significance level of 5%.
The reserves of power will be used to provide more power
to fine-tune the multivariate mixed-regression models and
associated secondary analyses.
Patients: each month, approximately 100 patients with
dizziness seek care at the six-hospital associated-EDs in
Nueces County, TX, USA. Over an 18-month period, we
anticipate a total sample size of approximately 1800. Ap-
proximately half of the 1800 patient visits will occur
prior to the intervention in the overall study. As dizzi-
ness volume can vary widely both within and across EDs
we have provided maximum sample sizes for each site
that are 200% of our initial estimates. After evaluating
initial accrual, a higher number of ED visits for dizziness
met our inclusion criteria, and as such we are now pro-
viding increased maximum sample sizes. Our revised
total expected enrollments will be 6800 with a revised
maximum of 10,800. We believe the higher-than-normal
number of visits likely relates to a lower threshold for
inclusion in the current study than in the study used for
preliminary estimates and an increase in dizziness pre-
sentations to the ED now compared with time of prelim-
inary estimates. In addition, a temporary closing of one
of the EDs is resulting in higher volumes in the others
EDs.
Data monitoring
The trial does not employ formal efficacy or futility stop-
ping rules. As a cluster-delivered educational interven-
tion to several hospitals, formal stopping boundaries for
efficacy or futility are not appropriate.
The Independent Medical Monitor (IMM) will review
primary endpoint data by group. The principal investiga-
tors (PIs) will review overall primary outcome data and
will remain blinded to performance by group. In
addition, the main safety endpoint (90-day stroke rate)
will be included for reporting to the investigators and
the IMM; it will be further classified as immediate diag-
nosis (at time of index ED primary dizziness visit) or de-
layed diagnosis (at some point during following 90 days).
A brief narrative will be provided with each stroke diag-
nosis, based on the linked record from the BASIC study
(i.e., 50-year-old woman with a middle cerebral artery
stroke 85 days after ED primary dizziness visit). A sum-
mary of SAEs and AEs meeting the DIZZTINCT defin-
ition for inclusion will also be routinely monitored by
the PIs and the IMM. Data quality will be assessed by
routine monitoring by the study project monitor, along
with review of the interview data that assesses patients
directly for the performance of BPPV care processes.
Data analyses
The intervention is delivered to hospitals. Intervention is
a binary variable with two levels, pre-intervention (no
intervention), post-intervention (under intervention).
The primary analysis will use binary logistic regression
and will include covariates for hospital, month (to handle
secular trends), and intervention (see below). Provider
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(attending physician) will be included as a random effect
(intercept). For a set of new patient visits, the binary ran-
dom variable DHT/CRM “yes/no” will serve as the pri-
mary response. Patient visits will be supplied with
patient-, hospital- and provider-level covariates as well as
the calendar time variable modeling the secular trend, and
the intervention yes/no variable measuring whether the
visit occurs under intervention or not. To take hospital-
and provider-specific unmeasured features into account,
hospital categorical variables will be included in the ana-
lysis and we will include random intercept for provider.
Due to the fact that the number of hospitals and providers
is much smaller than the number of patient visits, adjust-
ing for hospital and provider effects by way of categorical
variables will not lead to bias. Secondary analyses will ex-
plore alternative approaches using random effects (Gauss-
ian) models. A two-sided model-based test for the
intervention variable will be used to test the primary hy-
pothesis at the significance level of 5%. In addition, we will
report the observed proportions of the primary and sec-
ondary endpoints and the differences in proportions
stratified by treatment versus control. We do not plan to
adjust for repeated visits by a patient, as our primary end-
point was measuring provider actions (and repeated ED
visits by an individual patient over an 18-month period
are likely to have different symptoms and disease pro-
cesses.) We will create graphical plots of changes in the
primary, secondary, and selected exploratory endpoints
over time.
The secondary analysis (safety) will numerically
summarize the 90-day stroke rate – cumulatively and
stratified for stroke diagnosed on the index dizziness
visits and for post-index visit strokes (delayed diagnosis)
in patients seen at EDs with and without the interven-
tion. This is anticipated to be very rare. The intervention
does not target improving stroke diagnosis. However,
evaluating both the index visit stroke diagnosis rate and
the delayed diagnosis rate should allow for determin-
ation of major changes. We anticipate the index visit
stroke diagnosis rate to be approximately 2–3% and the
delayed diagnosis rate to be approximately 0.6% [29, 30].
Additional details of the planned analysis are included
with the draft statistical analysis plan (which will be fi-
nalized prior to the end of recruitment) as Additional
files 1, 2, 3, and 4.
Cost analysis
Cost analysis will be performed including inputs of tests,
medications, procedures, consultations, and level of visit.
Additional costs will also be gathered relating to hospital
admission and subsequent visits to the ED. Unit costs
will be derived from nationally representative sources
(e.g., Medicare fee schedule). Costs often have a skewed
distribution and thus will be transformed (typically a log
transformation) to achieve a more normal distribution.
The costs in patients treated by pre-intervention pro-
viders will be compared to costs in patients treated by
post-intervention providers using the t test and also a
generalized linear model (GLM). General concepts for
modeling costs will be followed, including adjusting for
secular trends.
Formative evaluations (FE)
We will conduct implementation- and progress-focused
formative evaluations during the course of implementa-
tion to monitor and identify potential and actual influ-
ences on the progress and effectiveness of the
implementation efforts [31]. We will monitor implemen-
tation fidelity through attendance at initial and follow-up
educational sessions, the use of the web-based decision
aid, and referral networks. Feedback will be solicited and
recorded at the initial and follow-up education sessions,
and the study team will determine the adjustments/adap-
tations in the strategy based on this feedback. At the con-
clusion of the implementation period, we will conduct
semi-structured interviews with key stakeholders (e.g.,
providers, local champions, project manager, referral net-
work members). The data will be analyzed qualitatively
using a grounded theory approach intended to inductively
find themes that could inform future intervention design
or implementation. The knowledge gained from FE will
inform needed adjustments, unanticipated consequences,
issues, and resolutions for future implementations.
Dissemination
The study team will present the results to the providers
in the community. In addition, the primary analysis will
be presented in a main paper. Data will be available to
interested scientists if appropriate data use agreements
are executed. Given that we have not collected persistent
contact information for the patients who contributed
data, we do not have plans to directly contact them.
Despite this, we will plan for press release(s) within the
community to share the results.
Discussion
This implementation research study uses a
stepped-wedge, randomized clinical trial design to assess
the impact a multi-faceted educational and care-process-
based intervention on the documentation of the DHT
and CRM in ED visits for dizziness. We plan to use the
results of this study to first determine whether it would
be worthwhile to proceed to a larger-scale study de-
signed to change physician practice within multiple
health systems. Key strengths of our approach is our use
of a community-based cohort of patients and health care
providers, and the addition of our infrastructure to an
existing stroke surveillance study – allowing us to more
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efficiently ensure that we did not increase the proportion
of patients who had missed strokes.
Limitations
The trial as designed, has some important limitations. First,
we only included six hospitals within a single geographic
community in the United States – and, as such, these find-
ings may not be generalizable to other settings. We hope that
what we learn from this exploratory phase trial will help us
design interventions that can impact a more diverse set of
EDs. Second, despite the large number of dizziness patients,
we anticipate that the number of outcome events (DHT or
CRM) will be relatively small, so larger studies will be needed
to more precisely understand the effects of our intervention.
Third, we did not allow for a third period surrounding the
time of the intervention at each site. Given that the effects of
the intervention are likely to be delayed, this means that we
will rely on observation of temporal trends within each site
to better understand the timing and durability of practice
change if the intervention is successful. Some aspects, such
as the checklist requested by the community physicians in
this study, will not have been in use long enough to be con-
sidered validated. As such, future studies may involve pro-
spective validation of some of the study elements. In
addition, we will need to use what we have learned in this
study to design processes to evaluate effects on patient out-
comes. Our study did not evaluate the effects of our inter-
vention on care processes for patients without dizziness and
this may be an interesting area for future study. A major as-
sumption of our preliminary study is that by encouraging
the use of the inexpensive, and evidence-based DHTs and
CRMs, we will translate prior, observed, improved patient
outcomes into the emergency setting. We will need to con-
firm the validity of this assumption in future trials.
Trial status
Recruitment began in October of 2016. This manuscript
was initially submitted in March 2018. We anticipate ac-
crual will continue to April 2018. We will evaluate for
stroke in accrued patients for 90 days following the end
of accrual. No protocol or statistical analysis plan
changes occurred between the submission of this paper
and the completion of data collection and analysis, with
the exception of the administrative adding or deletion of
personnel.
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